Established in 1904, the University of Leeds is one of the largest universities in the UK. We’re part of the Russell Group of research-intensive universities and are renowned globally for the quality of our research and teaching.
As the academic lead of WP5, the University of Leeds integrates extensive expertise in OA clinical research and will play a key role in developing and validating novel PROBE OA clinical trial designs.
More information:
This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under Grant Agreement No. 101219324.
The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, EuropaBio, MedTech Europe, Vaccines Europe, and Pacira Pharmaceuticals Inc., Capgemini Consulting, Nordic Bioscience Clinical Development A/S, and Apheris AI GmbH.
Funded by the European Union, the private members, and those contributing partners of the IHI JU. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them.
© 2026 | PROBE — Patient relevant osteoarthritis endpoints using big data evaluation
